In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with adjuvant pelvic radiation therapy. Risks of pelvic and para-aortic nodal recurrence and frequency of short-term side effects were greater for the brachytherapy-chemotherapy approach. High completion rates for each treatment arm suggest that both therapies are well-tolerated by patients. Findings were presented by Randall et al at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO) (Abstract LBA-1).
Clinical trials in the early 2000s found that external beam radiation therapy to the pelvis following surgery to remove early-stage endometrial cancer reduced tumor recurrence rates compared with postsurgical observation alone, which established adjuvant pelvic radiation as the standard treatment for stage I–II patients. In recent years, however, many physicians have begun treating early-stage patients at higher risk of recurrence with an alternative approach of vaginal cuff brachytherapy followed by chemotherapy. GOG-249 was designed to directly compare the two approaches.
GOG-249 was a phase III randomized trial designed to test whether adjuvant brachytherapy plus chemotherapy improved recurrence-free survival compared with the standard treatment of adjuvant pelvic radiation for early-stage, high-risk endometrial cancer. Eligible patients included women with high-risk stage I–II histology, including stage II tumors, stage I–II serous or clear-cell carcinomas, and stage I endometrioid tumors if the patient demonstrated clinic-pathologic features associated with a high risk of recurrence, based on criteria established in the GOG-33 trial and used in the GOG-99 trial.
Most patients (74%) had stage I disease and endometrioid histology (71% vs 15% serous and 5% clear-cell carcinomas). The median patient age was 63 years. All patients underwent hysterectomy prior to radiation or chemoradiation therapy.
One of two treatment arms was randomly assigned to patients: adjuvant external beam radiation therapy (RT) to the pelvis (PXRT) or vaginal cuff brachytherapy plus chemotherapy (VCB/C). The PXRT group (n = 301 patients) received a median radiation dose of 45 Gray (Gy) delivered over 5 weeks through standard four-field radiation or intensity-modulated radiation therapy (IMRT). Patients with serous, clear-cell or stage II tumors were eligible for a vaginal cuff brachytherapy boost, and 35% of the cohort received this additional therapy. The VCB/C group (n = 300 patients) received either high-dose rate (HDR) or low-dose rate (LDR) brachytherapy followed by three cycles of chemotherapy including paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6 every 21 days). Nearly all 601 patients accrued for the trial completed treatment (91% PXRT, 87% VCB/C).
There were no statistically significant increases in recurrence-free survival (RFS) or overall survival (OS) in the brachytherapy-chemotherapy arm. At a median follow-up of 53 months, 82% of patients were alive and recurrence-free at 3 years for both the VCB/C and PXRT patient groups. Three-year OS rates were 91% for pelvic radiation and 88% for the brachytherapy-chemotherapy combination, but this difference was not statistically significant (P = .57). Survival distributions were estimated using the Kaplan-Meier method and compared using a log rank test.
The cumulative incidence of pelvic or para-aortic nodal recurrence at 5 years among the VCB/C group (9.2%; 25 recurrences, 20 in the pelvis) was twice that of the pelvic radiation cohort (4.4%; 12 recurrences, 6 in the pelvis) (Hazard Ratio (HR) = 0.47, 95% CI 0.24–0.94). The cumulative incidence of vaginal and distant tumor recurrences, however, did not differ significantly between the groups. The cumulative incidence of distant recurrence at 5 years was 18% for both groups.
Short-term side effects were more pronounced on the brachytherapy-chemotherapy arm, while long-term side effects were similar for both treatments. Grade 3 or higher adverse events were reported in 187 patients receiving VCB/C, compared with 32 patients in the PXRT group. Severe late effects were reported in 35 patients who received VCB/C and 37 who received PXRT. Side effects were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 3.
“Our trial clearly demonstrates that adjuvant pelvic radiation should remain the standard of care for high-risk, early-stage endometrial cancer patients. It also suggests that the trend in our field of abandoning pelvic radiation in favor of chemotherapy-brachytherapy combinations for high-risk patients is premature and not supported by clinical evidence,” said Marcus Randall, MD, FASTRO, lead author of the study and Professor of Radiation Medicine at the University of Kentucky in Lexington. “The cohort of women with high-risk histologies did not demonstrate any benefit from the addition of chemotherapy, but they did experience worse nodal control rates and more short-term side effects.”
“Previous GOG trials confirmed that pelvic radiation is an effective, safe, and tolerable option to manage early-stage endometrial cancer. The current trial confirms that this standard treatment is preferable to the experimental approach of vaginal cuff brachytherapy followed by chemotherapy, in terms of tumor control in the nodal regions and also in terms of acute toxicity. This finding holds true even for patients at a higher risk of recurrence,” said Dr. Randall. “Researchers can focus now on determining the optimal radiation dosing and fractionation schedules for various patient subgroups, as well as refining the techniques we use to deliver external beam therapy to the pelvis and continue to investigate therapies to decrease distant failures in this high-risk group.”
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.